Navigation

ExploreAnalysisInvestor RelationsAI AssistantCompareScreener
LoginSign Up FreeSign Up
BI

BIIB

Market Closed

Biogen Inc.

NASDAQHealthcareDrug Manufacturers - General
US
7.50K employees
CEO: Christopher A. Viehbacher
Founded: 1991
$253.40
+$0.00(+NaN%)
Market Cap
37.46B
Beta
0.17
52W Range
N/A
Dividend Yield
0.00%
OverviewForecastsFundamentalMarket SentimentValuationOwnership
OverviewForecastsFundamentalMarket SentimentValuationOwnership
Comprehensive Valuation
In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Biogen’s current price shows a 32.9% implied upside against a high-confidence fair value of $336.69, suggesting undervaluation. Monte Carlo analysis indicates substantial volatility (CV 196.33%) with 22.2% downside risk below current price, reflecting high uncertainty despite attractive median and base case valuations. Financial health reveals strong liquidity but weak growth and profitability, adding nuance to risk assessment.
Enhanced Football Field Analysis
Loading comprehensive valuation data...

Fetching multi-methodology valuation ranges...

Explore BIIB

Overview

Key metrics and AI-powered insights

Forecast

Price targets and earnings estimates

Fundamentals

Income, balance sheet and cash flow

Valuation

P/E, DCF and valuation multiples

Ownership

Institutional and insider holdings

Sentiment

Analyst ratings and news sentiment

BIIB in the Healthcare

Large Cap
Healthcare

Browse sector stocks →

Drug Manufacturers - General

Browse industry stocks →

© 2026 MarketCI. All rights reserved.

HelpPricingPrivacyTerms